Secondary Logo

Journal Logo

Combination cardiovascular drugs

Dalal, Kavitha S. PharmD; Bridgeman, Mary Barna PharmD, BCPS

doi: 10.1097/01.NURSE.0000521021.69520.76
Department: DRUG CHALLENGE
Free

Kavitha S. Dalal is a critical care pharmacist at Virtua in Marlton, N.J. Mary Barna Bridgeman is a clinical associate professor at Rutgers University Ernest Mario School of Pharmacy in Piscataway, N.J.

Unless otherwise specified, the information in the preceding summaries applies to adults, not children. Consult the package insert for information about each drug's safety during pregnancy and breastfeeding. Also consult a pharmacist, the package insert, or a comprehensive drug reference for more details on precautions, drug interactions, and adverse reactions.

Can you identify these combination cardiovascular drugs? To find out, match each brand name in Section I with its generic name in Section II.

Back to Top | Article Outline

Section I

______ 1. Byvalson (Allergan USA)

______ 2. Yosprala (Aralez Pharmaceuticals U.S.)

______ 3. Entresto (Novartis)

______ 4. Prestalia (Symplmed)

Back to Top | Article Outline

Section II

a. sacubitril and valsartan. These film-coated tablets combine an angiotensin II receptor blocker (ARB) and a neprilysin inhibitor. This drug is indicated to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.

b. perindopril and amlodipine. Indicated to manage hypertension, this drug combines an angiotensin-converting enzyme inhibitor and a dihydropyridine calcium channel blocker. This drug isn't recommended for use in patients with severe renal impairment.

c. nebivolol and valsartan. This drug, indicated to treat hypertension, is a combination of a beta-1 selective beta-blocker and an ARB. It can be administered with or without food. Warn patients not to discontinue the drug abruptly. In general, patients with bronchospastic disorders should avoid beta-blockers.

d. aspirin and omeprazole. Combining an antiplatelet agent and a proton pump inhibitor, this drug is indicated to reduce the risk of aspirin-associated gastric ulcers in at-risk patients who need aspirin for secondary prevention of cardiovascular and cerebrovascular events. Teach patients to take each daily dose at least 1 hour before a meal, and warn them not to split, chew, crush, or dissolve the tablets.

Resources available upon request.

ANSWERS: 1c, 2d, 3a, 4b

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.